Risks

Orthopedic procedure volumes remain sensitive to elective-surgery timing and hospital staffing, leaving ZBH more exposed than diversified medtech peers with broader acute-care demand.

Pricing pressure from large hospital and GPO customers can compress implant margins, while peers with stronger consumables mix or service revenue typically defend pricing better.

Inventory-heavy channel dynamics and long cash conversion cycles increase working-capital drag, making ZBH less efficient than leaner peers if demand normalizes unevenly.

Leverage near 3.6x net debt/EBITDA and interest coverage around 4.6x limit flexibility versus stronger-balance-sheet peers, raising sensitivity to slower recovery or refinancing costs.

Opportunities

A sustained rebound in elective orthopedic procedures would lift hip and knee demand, and ZBH is well positioned versus smaller peers with narrower product breadth.

Aging populations and higher musculoskeletal treatment rates support multi-year procedure growth, with ZBH benefiting more than peers lacking global scale and surgeon relationships.

Product refreshes and broader implant portfolios can support share gains in reconstruction and sports medicine, where ZBH’s installed base is more defensible than smaller competitors.

International expansion offers incremental growth as reimbursement and access improve, and ZBH’s global footprint is broader than many U.S.-centric orthopedic peers.

Overall Score

ZBH’s forward positioning is supported by elective-procedure recovery, demographic demand, and global scale, while margin pressure, working-capital intensity, and leverage keep risks meaningful versus peers.